Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma

Summary

In this multinational Phase III study the efficacy and safety of 10 µM AP 12009 is compared to standard chemotherapy (temozolomide or BCNU or CCNU) in adult patients with confirmed recurrent or refractory anaplastic astrocytoma (WHO grade III) or secondary glioblastoma (WHO grade IV).

Timeline

Start

2008-12

Primary completion

2012-02

Completion

2012-06

Outcome

Outcome not reported

Stopped (Enrollment): “Unable to recruit the projected patient number. All analyses are descriptive, only.”

Drugs

Indications